England: HTA Body’s Income Hit By COVID-19
Executive Summary
England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.
You may also be interested in...
Tumor-Agnostic First In England As NICE Reverses Vitrakvi Rejection
Bayer’s “game-changing” histology-independent treatment is to be made available via the Cancer Drugs Fund.
UK’s NICE Under Fire For New HTA Fees
Fees for appraisals that the health technology assessment body, NICE, will introduce in April could adversely impact companies with medicines for smaller indications, despite a bigger fee reduction for some manufacturers.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.